Risk of mortality in patients with cancer who experience febrile neutropenia

Cancer

Volumn 116, Issue 23, 2010, Pages 5555-5563

  Lyman, Gary H ^a   Michels, Shannon L ^b   Reynolds, Matthew W ^b   Barron, Rich ^c   Tomic, Karen Smoyer ^d   Yu, Jingbo ^d  

^a DUKE CANCER INSTITUTE   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c AMGEN INC   (United States)

^d HEALTHCORE INC   (United States)

Author keywords

chemotherapy; infection; mortality; neutropenia; propensity score

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MORTALITY; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; FEMALE; FEVER; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 78649564296     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25332     Document Type: Article

References (29)

1. Crawford J, Dale DC, Lyman GH,. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100: 228-237.
2. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106: 2258-2266.
3. Lyman GH, Kuderer NM,. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003; 1: 23-35.
4. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008; 6: 109-118.
5. Lyman GH, Delgado DJ,. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003; 98: 2402-2409.
6. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003; 44: 2069-2076.
7. Lyman GH, Lyman CH, Agboola O,. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005; 10: 427-437.
8. Pizzo PA,. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993; 328: 1323-1332.
9. Barron RL,. Pathophysiology of septic shock and implications for therapy. Clin Pharm. 1993; 12: 829-845.
10. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from 2 decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247-259.
11. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in 6 European audits of breast cancer treatment. Support Care Cancer. 2006; 14: 901-909.
12. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008; 6: 122-174.
13. Chang J,. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000; 36 (suppl 1): S11-S14.
14. Skipper HE,. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971; 28: 1479-1499.
15. Bonadonna G, Moliterni A, Zambetti M, et al. 30 Years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study [serial online]. BMJ. 2005; 330: 217.
16. Bonadonna G, Valagussa P,. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304: 10-15.
17. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332: 901-906.
18. Bonneterre J, Roche H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2005; 23: 2686-2693.
19. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998; 90: 1205-1211.
20. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963-977.
21. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992; 80: 1430-1436.
22. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25: 3158-3167.
23. Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008; 11: 172-179.
24. Kern WV,. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006; 42: 533-540.
25. Rosenbaum P, Rubin D,. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Amer Statist. 1985; 39: 33-38.
26. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
27. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Fort Washington, Pa: National Comprehensive Cancer Network; 2007.
28. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G,. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008; 19: 454-460.
29. Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control. 2006; 17: 647-654.